Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Julie E. Bauman(George Washington University), Laura P. Stabile(University of Pittsburgh), Umamaheswar Duvvuri(City University of New York), James Ohr(University of Pittsburgh), Robert L. Ferris(University of Pittsburgh), Jennifer R. Grandis(University of California, San Francisco), Jonas T. Johnson(University of Pittsburgh), Seungwon Kim(UPMC Hillman Cancer Center), William E. Gooding(UPMC Hillman Cancer Center)
Cited by 2
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Head and neck squamous cell carcinoma
|Nature Reviews Disease Primers|2020|4k
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
|JAMA Oncology|2016|1.4k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688